SpyGlass Pharma Inc., a biopharmaceutical company focused on drug delivery solutions for chronic eye conditions, has established its new, larger headquarters in Irvine. The company moved last month into a two-story, 33,000-square-foot building designed for commercialization efforts. This new facility has the capacity to accommodate up to 150 employees, which triples the headcount capacity from its previous office in Aliso Viejo.
Chief Executive Patrick Mooney stated that the company is "building this company for decades," moving beyond its initial growth phase. This expansion follows SpyGlass Pharma going public in February, an event that raised $172.5 million in gross proceeds. Since its initial public offering, the company's workforce has grown by 33%, now employing more than 85 individuals. The company's stock has also seen significant growth since its IPO at $16 per share, with shares trading at $28.99, contributing to a market capitalization of $970 million at press time.
SpyGlass is currently in the midst of two ongoing Phase 3 trials for its primary product, the BIM-IOL system. This implant is designed to deliver glaucoma medication into the eye for up to three years, potentially eliminating the need for daily eye drops. Enrollment for both trials is anticipated to conclude next year, with a New Drug Application (NDA) planned for 2028. The company is targeting a launch of the BIM-IOL system in 2029. Mooney noted that the launch readiness team is actively meeting, indicating that planning is already in rhythm, three years ahead of the intended launch.
The new Irvine headquarters consolidates the company's operations, bringing research and development functions under the same roof as other activities. Previously, R&D was housed in a separate facility at the Aliso Viejo location. The new facility also features a dedicated surgical suite for product demonstrations, which Chief Operating Officer James Dennewill indicated will allow SpyGlass to engage with more surgeons as the company prepares for commercialization. Dennewill added that the company works with 90 clinical sites in its Phase 3 trials, and the suite will facilitate introducing the product to a broader audience. SpyGlass developed its own drug manufacturing and testing processes early on, which Dennewill stated is central to achieving "consistent, multi-year drug delivery." The facility can produce thousands of parts for testing.
In May, SpyGlass announced that the American Medical Association (AMA) approved a new add-on Category III code for the attachment and insertion of the BIM-IOL system during cataract surgery. Mooney described this as a key step in addressing common questions about reimbursement for the product. This code aids in tracking the utilization of emerging technologies and procedures and supports the FDA approval process.
Addressing patient needs beyond the three-year treatment window, SpyGlass has also developed a next-generation sustained-release implant called the BIM-DRS (Drug Ring System). Designed to be a retreatment option for patients who have previously received a SpyGlass IOL, the BIM-DRS will accommodate a larger drug payload and is intended to extend treatment duration to as long as seven years. Mooney described BIM-DRS as a "huge multiplier" for SpyGlass, suggesting it could increase the company's addressable market by six to eight times. First-in-human trials for BIM-DRS are expected to commence before the end of this year. Additionally, the company is focused on publishing four-year clinical data for the BIM-IOL system, building on initial patients from its feasibility study, which three-year data confirmed provided "sustained, predictable dosing."
This move marks a return to Irvine for SpyGlass Pharma, as the company began its operations in 2021 at University Lab Partners (ULP), a nonprofit life science incubator within UCI Research Park. Dennewill highlighted ULP as a valuable resource for lab capacity during the company's early stages. The City of Irvine supported SpyGlass' relocation through its Navigator Program, which provides a dedicated point of contact to streamline city requirements. Dennewill noted this program was "critical" due to the tight moving schedule, which provided a limited window for variability.
Karin Koch, director of economic development for the City of Irvine, noted that the city is investing in creating more resources similar to ULP to support startups. This includes the new Irvine Center of Innovation & Entrepreneurship, a 25,000-square-foot center launched in July. Slated to open in the second quarter of 2027, this center will offer office and lab coworking space, access to capital, and business advisory expertise for companies in medtech, life sciences, biotechnology, AI, cybersecurity, and aerospace. Located on Sand Canyon within the healthcare corridor, the center is backed by $7.7 million, including federal funds and private donations. Koch stated there is a "growing demand to be closer to where the employment hub is." She also noted that the push to attract and support healthcare companies comes as Irvine approaches buildout, with city revenue "highly dependent on real estate."
